Treating patients with Theranostics

Theranostics is a treatment combining diagnostic imaging to locate specific receptors on cancer cells followed by precision treatment that target these receptors specifically


Who may benefit?

Theranostics can be used to treat cancers that have spread (metastasised), or where cancer is advanced and/or hasn’t responded to other treatments.

While in the future theranostics may be used for different cancers, to date most experience and success has been in metastatic prostate cancer and neuroendocrine tumours.

Metastatic prostate cancer



How it works

Theranostics is a personalised approach to treating cancer, using both diagnosis and therapy tools as part of the treatment.

Theranostics uses PET scan imaging (a special type of scan) to see if specific targets, known as tumour receptors, are present on tumour cells. If these targets are present and visible on the scan, a radioactive drug is used to treat the tumours. The drug is given as an injection and selectively targets the tumour cells while avoiding healthy areas. Most of the radioactive drug that doesn’t reach the target is quickly passed out of the body.



Theranostics is not suitable for all patients, but may be an option in metastatic disease unresponsive to or unsuitable for conventional therapies. Most evidence to date is in metastatic castrate resistant prostate cancer and advanced neuroendocrine tumours (NETs).

  • A Phase 2 study (n=30) of 177Lu-PSMA-617 showed ‘high response rates, low toxicity effects, and a reduction in pain in men with metastatic castration-resistant prostate cancer who have progressed after conventional treatments’1.
  • In Phase 3 study, NETTER–1*, ’177Lu-Dotatate resulted in markedly longer progression-free survival than high-dose octreotide LAR and was associated with limited acute toxic effects in a population of patients who had progressive neuroendocrine tumours that originated in the midgut’2.


Available services

  • 177Lutetium PSMA – for Metastatic or Treatment Resistant Prostate Cancer
  • 177Lutetium Octreotate – for somatostatin receptor – positive tumours (available from Autumn 2019)

Easy access

Cancer treatment at GenesisCare may be covered by insurance. We also offer self-pay options for Theranostics.

How to refer a patient

Please send a referral/clinic letter to

For more information

Contact us directly
Tel: 01753 418 444


Little Aston Hall Drive, Sutton Coldfield, B74 3BF

+44 (0)121 514 1185


300 Park Avenue, Aztec West, Bristol, BS32 4SY

+44 (0)1454 642801


Fordham Rd, Newmarket CB8 7XN, UK

+44 (0)1223 633 664


Springfield Cancer Centre, Lawn Lane, Chelmsford, CM1 7GU

+44 (0)1245 676 351

Cromwell Hospital

164-178 Cromwell Rd, Kensington, London SW5 0TU, UK

+44 (0)203 613 9355


Unit 710, Centennial Park, Centennial Avenue, Elstree, Borehamwood, WD6 3SZ

+44 (0)203 613 9356


BMI St Martha Oncology Centre, 46 Harvey Road, Guildford, GU1 3LX

+44 (0)1483 676 898


17 Kings Hill Avenue, Kings Hill, West Malling, ME19 4UA

+44 (0)1732 386 599

Milton Keynes

Sunrise Parkway, Linford Wood East, Milton Keynes, MK14 6LS

+44 (0)1908 448 166


The Park Centre for oncology, Sherwood Lodge Drive, Burntstump Country Park, Nottingham, NG5 8RX

+44 (0)1156 762 989


Peters Way, Sandy Lane West, Oxford, OX4 6LB

+44 (0)1865 224 884


Bartons Road, Havant, PO9 5NA

+44 (0)23 9280 0102


Spire Hospital, Chalybeate Close, Southampton, SO16 6UY

+44 (0)238 008 5138


69 Alma Road, Windsor, SL4 3HD

+44 (0)1753 465 493

Search for a centre near you

Multiple selected

1. Hofman, et al. Lancet Oncol; 2018; 19: 825–33
2. Strosberg, et al. N Engl J Med; 2017; 376: 125-135